Of importance, a recent post hoc analysis of a multicentre open-label RCT (SURPASS-3), where 246 individuals with T2D received either tirzepatide or insulin glargine [127] assessed the use of GLP-1 RA on muscle composition in patients with T2D, overweight and obesity. Here, GLP1R is linked to Obesity.